Subacute Cutaneous Lupus Erythematosus

Alniemi, Dema T.; Gutierrez, Albert; Drage, Lisa A.; Wetter, David A.

doi:10.1016/j.mayocp.2016.10.030

Cited by 28 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with systemic features in association with mAbinduced SCLE exhibited a similarly mild course to that reported in DI-SCLE [19], with no cases of lupus nephritis or CNS involvement [42]. Lesions over the legs have been depicted as being more typical of DI-SCLE than idiopathic SCLE [43], which was supported by our finding of 30% of patients with leg involvement.…”

Section: Clinical Associationssupporting

confidence: 82%

“…Previous reviews on the patient demographics of DI-SCLE and non-DI-SCLE cases found comparable characteristics as those identified in this review [42][43][44][45]. Similar to other patients with DI-SCLE, mAb-induced SCLE most commonly occurred in White female patients with a mean age of diagnosis between 40 and 65 years [14,42], suggesting common susceptibility factors or simply reflecting the majority demographic of patients being administered these medications. The time course of mAb-induced SCLE was similar to a series of DI-SCLE where a median of 3-8 weeks to onset and 4-9 weeks to resolution was reported [43,45].…”

Section: Clinical Associationssupporting

confidence: 73%

“…TNFɑ is a cytokine involved in myriad signalling pathways of apoptosis, inflammation and immune regulation depending on the cellular context [59][60][61]. This wide array of cellular effects in different cell types may account for the conflicting findings of both the beneficial and antagonistic effects of TNFɑ on lupus in animal models [62,63] and a small number of case reports [42,64]. The significance of specific TNF pathways, and even anti-TNF mechanisms, are not well understood in CLE [65].…”

Section: Mab Usementioning

confidence: 99%

See 2 more Smart Citations

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

et al. 2020

View full text Add to dashboard Cite

Background Subacute cutaneous lupus erythematosus (S(CLE) lacks consensus diagnostic criteria and the pathogenesis is poorly understood. There are increasing reports of SCLE induced by monoclonal antibodies (mAbs), but there are limited data on the aetiology, clinical characteristics and natural course of this disease. Methods We devised a set of diagnostic criteria for SCLE in collaboration with a multinational, multispecialty panel. This systematic review employed a two-layered search strategy of five databases for cases of mAb-induced SCLE (PROSPERO registered protocol CRD42019116521). To explore the relationship between relative mAb use and the number of SCLE cases reported, the estimated number of mAb users was modelled from 2013 to 2018 global commercial data and estimated annual therapy costs. Results From 40 papers, we identified 52 cases of mAb-induced SCLE, occurring in a cohort that was 73% female and with a median age of 61 years. Fifty percent of cases were induced by anti-tumour necrosis factor (TNF)-ɑ agents. A median of three drug doses preceded SCLE onset and the lesions lasted a median of 7 weeks after drug cessation. Oral and topical corticosteroids were most frequently used. Of the licensed mAbs, adalimumab, denosumab, rituximab, etanercept and infliximab were calculated to have the highest relative number of yearly users based on global sales data. Comparing the number of mAb-induced SCLE cases with estimated yearly users, the checkpoint inhibitors pembrolizumab and nivolumab showed strikingly high rates of SCLE relative to their global use, but ipilimumab did not. Conclusion We present the first systematic review characterising mAb-induced SCLE with respect to triggers, clinical signs, laboratory findings, prognosis and treatment approaches. We identify elevated rates associated with the use of checkpoint inhibitors and anti-TNFɑ agents.

show abstract

Section: Clinical Associationssupporting

confidence: 82%

Section: Clinical Associationssupporting

confidence: 73%

Section: Mab Usementioning

confidence: 99%

See 1 more Smart Citation

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

et al. 2020

View full text Add to dashboard Cite

show abstract

“…SCLE is highly associated with ANA and anti-SS-A/Ro positivity [ 33 – 35 ]. One recent retrospective review of 90 SCLE patients demonstrated 89% ANA positivity and 99% anti-SS-A/Ro positivity [ 33 ], while another Italian study demonstrated strong associations of SCLE with anti-SS-A/Ro, anti-Smith, and anti-ribonucleoprotein (anti-RNP) antibodies [ 36 ]. Caucasian race and smoking are also associated with increased risk of SCLE.…”

Section: Cutaneous Manifestations Of Lupusmentioning

confidence: 99%

“…As many as 20 to 50% of patients with SCLE will go on to meet criteria for SLE, but these patients tend to have a milder disease phenotype with less internal organ manifestations of disease than the typical SLE patient [ 37 , 38 ]. SCLE may also be seen in patients with primary Sjӧgren's syndrome [ 33 ].…”

Section: Cutaneous Manifestations Of Lupusmentioning

confidence: 99%

Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond

Cooper

Pisano

Shapiro

2021

International Journal of Rheumatology

View full text Add to dashboard Cite

Lupus, Latin for “wolf,” is a term used to describe many dermatologic conditions, some of which are related to underlying systemic lupus erythematosus, while others are distinct disease processes. Cutaneous lupus erythematosus includes a wide array of visible skin manifestations and can progress to systemic lupus erythematosus in some cases. Cutaneous lupus can be subdivided into three main categories: acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. Physical exam, laboratory studies, and histopathology enable differentiation of cutaneous lupus subtypes. This differentiation is paramount as the subtype of cutaneous lupus informs upon treatment, disease monitoring, and prognostication. This review outlines the different cutaneous manifestations of lupus erythematosus and provides an update on both topical and systemic treatment options for these patients. Other conditions that utilize the term “lupus” but are not cutaneous lupus erythematosus are also discussed.

show abstract

Lupus Erythematosus and Antiphospholipid Syndrome

Dutz,

Khosravi‐Hafshejani

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Lupus erythematosus is an autoimmune disease that commonly affects the skin, and may present with cutaneous only disease. This chapter reviews the forms of cutaneous lupus‐specific skin disease (discoid lupus, subacute cutaneous lupus, lupus tumidus and acute cutaneous lupus), their clinical features, pathogenesis and treatment. A review of systemic lupus erythematosus is also provided with a discussion of diagnosis, clinical features, cutaneous aspects and treatment, germane for the dermatologist. Clinical features of neonatal lupus erythematosus and the antiphospholipid antibody syndrome, more commonly seen in systemic lupus erythematosus kindreds, are also discussed.

show abstract

Subacute Cutaneous Lupus Erythematosus

Cited by 28 publications

References 23 publications

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond

Lupus Erythematosus and Antiphospholipid Syndrome

Contact Info

Product

Resources

About